PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcamBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Complementary and Alternative Medicine
 
BMC Complement Altern Med. 2017; 17: 222.
Published online 2017 April 20. doi:  10.1186/s12906-017-1734-z
PMCID: PMC5397752

HVC1 ameliorates hyperlipidemia and inflammation in LDLR−/− mice

Abstract

Background

HVC1 consists of Coptidis Rhizoma (dried rhizome of Coptischinensis), Scutellariae Radix (root of Scutellariabaicalensis), Rhei Rhizoma (rhizome of Rheum officinale), and Pruni Cortex (cortex of Prunusyedoensis Matsum). Although the components are known to be effective in various conditions such as inflammation, hypertension, and hypercholesterolemia, there are no reports of the molecular mechanism of its hypolipidemic effects.

Methods

We investigated the hypolipidemic effect of HVC1 in low-density lipoprotein receptor-deficient (LDLR−/−) mice fed a high-cholesterol diet for 13 weeks. Mice were randomized in to 6 groups: ND (normal diet) group, HCD (high-cholesterol diet) group, and treatment groups fed HCD and treated with simvastatin (10 mg/kg, p.o.) or HVC1 (10, 50, or 250 mg/kg, p.o.).

Results

HVC1 regulated the levels of total cholesterol, triglyceride (TG), low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol in mouse serum. In addition, it regulated the transcription level of the peroxisome proliferator-activated receptors (PPARs), sterol regulatory element-binding proteins (SREBP)-2, 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase, lipoprotein lipase (LPL), apolipoprotein B (apo B), liver X receptor (LXR), and inflammatory cytokines (IL-1β, IL-6, and TNF-α). Furthermore, HVC1 activated 5′ adenosine monophosphate-activated protein kinase (AMPK).

Conclusion

Our results suggest that HVC1 might be effective in preventing high-cholesterol diet-induced hyperlipidemia by regulating the genes involved in cholesterol and lipid metabolism, and inflammatory responses.

Keywords: Hyperlipidemia, HVC1, PPAR, AMPK, Inflammatory cytokine, LDLR−/−

Background

Hyperlipidemia is defined as increased levels of cholesterol, cholesterol esters, phospholipids, and triglycerides in the serum [1]. About 20–25% of total daily cholesterol production occurs in the liver, which is also the organ that regulates cholesterol homeostasis. Cholesterol synthesis in the liver is responsive to external factors and hence, suppressed by an increase in dietary cholesterol. Triglycerides and cholesterol both from diet and synthesized in the liver are solubilized in lipoproteins [2]. These lipoproteins contain triglyceride lipid droplets and cholesteryl esters surrounded by polar phospholipids and proteins identified as apolipoproteins. There are several types of lipoproteins in the blood. In order of increasing density, they are chylomicrons, very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL), and high-density lipoprotein (HDL). Lower protein/lipid ratios yield less dense lipoproteins. The cholesterol within different lipoproteins is identical although some is carried as “free” alcohol and others as fatty acyl esters, known also as cholesterol esters. Low-density lipoprotein receptors (LDLR) regulate cholesterol-rich IDL and LDL in serum; therefore, LDLR deficiency is related to elevated cholesterol levels, particularly IDL/LDL cholesterol [3]. LDLR−/− mice demonstrate a human-like lipoprotein profile characterized by elevated cholesterol levels [4].

Peroxisome proliferator-activated receptors (PPARs) family is nuclear receptors superfamily that regulates in energy homeostasis and metabolic function such as β-oxidation of fatty acids, cholesterol metabolism [5]. The PPAR subfamily is composed of three members including PPAR-α, PPAR-δ, and PPAR-γ [6]. PPAR-α is known to regulation of genes involved in fatty acid oxidation, gluconeogenesis, cholesterol catabolism, and lipoprotein metabolism [7, 8]. Ligands for PPAR-α reduce triglycerides and LDL-cholesterol, and increase HDL-cholesterol and cholesterol efflux by inducing the expression of LXR [9, 10]. PPAR-δ regulates the expression of oxidative enzymes, and metabolic activity in the skeletal muscles, liver, and heart [11]. In addition, PPAR-δ may improve blood lipids and lipoproteins in atherosclerotic condition [12]. PPAR-δ agonist suppressed atherosclerotic lesion by improving the serum lipoprotein profiles [13]. Some studies have indicated that PPARs regulate the factors involved in fatty acid oxidation in the liver, and that PPAR-γ plays an important role in lipogenesis [1416]. PPAR-γ is involved in the expression of lipogenic enzymes [17]. The herbal materials in HVC1, namely Coptidis Rhizoma (CR, rhizome of Coptischinensis), Scutellariae Radix (SR, radix of Scutellariabaicalensis), Rhei Rhizoma (RR, rhizome of Rheum officinale), and Pruni Cortex (PC, cortex of Prunusyedoensis Matsumare used as traditional medicines. The main bioactive compounds of CR are coptisine which improved obesity-related inflammatory response in syrian golden hamsters [18]. CR extract is reported to reduce oxidative stress and cholesterol levels [19] and the bioflavonoids from SR suppress the level of serum lipid [20] and RR possess hypolipidemic effects in hyperlipidemic rat model [21]. Among the components of HVC1, PC is reported to effective in cough, urticarial, dermatitis, and asthma [22, 23]. In addition, in our previous study, we found that prunetin, a component of Pruni Cortex, indicated anti-obesity effect via suppressing of adipogenesis [24].

In this study, we investigated HVC1’s potential to suppress high-cholesterol diet (HCD)-induced hyperlipidemia, and explored the possible molecular mechanism involved in the attenuation of lipid metabolism and hepatic inflammation.

Methods

Reagents

Monoclonal antibodies were purchased from Santa Cruz Biotechnology (California, USA). Oligonucleotide primers were purchased from Bioneer (Daejeon, Republic of Korea). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Preparation of HVC1

Pruni Cortex and Rhei Rhizome were purchased from Dongwoodang Co., Ltd. (Yeongcheon, Kyungpook, Republic of Korea). Coptidis Rhizoma and Scutellariae Radix were purchased from Dong Yang Herb Co., Ltd. (Seoul, Republic of Korea) [25]. The herbs were used at a ratio of 1:1:2:2 (CR 300 g: SR 300 g: PC 600 g: RR 600 g) respectively. The herbs were extracted using 30% (v/v) ethanol in water at 60 °C for 8 h. The extracts were filtered through a 10 μm cartridge paper, and the ethanol was removed by vacuum rotary evaporation (EYELA, Tokyo, Japan). The concentrates were freeze-dried, and the yield was calculated to be 13%. The powders were dissolved in distilled water for the experiments, and the residual powder was stored at −20 °C.

Experimental animals

LDL−/− mice (4 weeks old, male) were purchased from Daehan Biolink Co. Ltd. (Daejeon, Republic of Korea) and maintained under constant conditions (temperature, 22 ± 3 °C; humidity, 40–50%; light/dark cycle 12/12 h). Mice were adapted to the feeding conditions for 1 week and then given free access to food and tap water for 13 weeks. Mice were randomly separated into groups of 6 each (Table (Table1):1): ND (normal diet) group, HCD (high-cholesterol diet) group, and treatment groups fed HCD (D12336) and treated with simvastatin (10 mg/kg, p.o.) or HVC1 (10, 50, or 250 mg/kg, p.o.). With the exception of the ND group, all of the mice were fed a HCD. Body weight and dietary intake were recorded every week. At the last day of 13th week, the animals were fasted overnight. Blood samples were collected by cardiac puncture. The liver was excised, rinsed and directly stored at −80 °C until analyses. All procedures were conducted in accordance with the National Institute of Health guidelines and approved by the Ethical Committee for Animal Care and the Use of Laboratory Animals of Sangji University (reg.no. 2014–04).

Table 1
Caloric content and ingredient composition of each diet

Histological examination

To analysis of atherosclerosis, aorta roots were frozen in embedding media for Oil red O staining analysis. The aorta roots were sectioned at a thickness of 7 μm at −20 °C by using a CM3050 cryostat (Leica, Wetzlar, Germany). The slides were fixed and stained with Oil red O dye (sigma). After staining, the slides were washed three times with 1, 2-propranediol (85%) and then with deionized water. Images were acquired using an SZX10 microscope (Olympus, Tokyo, Japan). The fold change of Oil red O positive area was quantified using Adobe Photoshop 9.0.

Analysis of serum lipid profiles

Blood samples were collected and centrifuged at 1003 × g, for 15 min at room temperature to obtain serum samples. Unused samples were immediately frozen at −70 °C for later measurements. Serum concentrations of total cholesterol (TC), LDL cholesterol, HDL-cholesterol and triglycerides were determined by enzymatic methods with commercial kits (BioVision, Milpitas, California, USA).

Western blot analysis

Liver tissues were homogenized in PRO-PREP™ protein extraction solution (Intron Biotechnology, Seoul, Republic of Korea) and incubated for 20 min at 4 °C. Debris was removed by micro-centrifugation11000 xg, followed by quick freezing of the supernatants. The protein concentration was determined using the Bio-Rad protein assay reagent according to the manufacturer’s instructions (Bio-Rad, California, USA). Proteins were electro-blotted onto a polyvinylidene difluoride (PVDF) membrane following separation on a 10–12% SDS polyacrylamide gel. The membrane was incubated for 1 h with blocking solution (5% skim milk) at room temperature, followed by incubation overnight with primary antibodies including, PPAR-γ, SREPB-2, HMGCR, phosphor-AMPK, AMPK (dilution, 1:1000), β-actin (dilution, 1:2000) at 4 °C. Blots were washed three times with Tween 20/Tris-buffered saline (T/TBS) and incubated in a horseradish peroxidase-conjugated secondary antibody (dilution, 1:2500) for 2 h at room temperature. The blots were again washed three times with T/TBS, and then developed by enhanced chemiluminescence (GE Healthcare, Wisconsin, USA).

RNA separation and quantitative real-time PCR (qRT-PCR) analysis

The liver tissues were homogenized, and total RNA was isolated using a Trizol reagent (Invitrogen, Carlsbad, California, USA). cDNA was obtained using isolated total RNA (1 μg), d(T)16 primer, and AMV reverse transcriptase. Relative gene expression was quantified using real-time PCR (Real Time PCR System 7500, Applied Biosystems, California, USA) with SYBR green PCR master mix (Applied Biosystems). The gene Ct values of PPARs, HMGCR, SREBP-2, apoB, LPL, LXR and inflammatory cytokines were normalized using gene express 2.0 program (Applied Biosystems) to the Ct value of GAPDH. Oligonucleotide primers were purchased from Bioneer (Deajeon, Republic of Korea) (Table (Table2).2). The total reaction volume was 20 μl and consisted of 1 μl cDNA, 0.4 μl of primers, 10 μl SYBR green master mix and 8.2 μl DEPC treated water (Intron Biotechnology, Seoul, Republic of Korea).

Table 2
Primer sequences

Statistical analysis

Data are expressed as mean ± standard deviation (SD) of triplicate experiments. Statistically significance was determined using ANOVA and Dunnett’s post hoc test, and P-values of less than 0.05 were considered statistically significant.

Results

Effects of HVC1 on plaque formation and serum lipid profiles in HCD-fed LDLR−/− mice

To investigate the effect of HVC1 on atherosclerosis, we examined Oil red O-stained lesions in the aortic roots. The plaque formation indicated as relative fold change of Oil red O positive area in HCD-fed LDLR−/− mice was almost 1.6 times higher than that in the ND group. In contrast to the HCD group, HVC1 administration significantly suppressed the plaque formation in dose-dependent manner in LDLR−/− mice fed HCD (Fig. (Fig.1a1a and andbb).

Fig. 1
Effect of HVC1 on plaque formation in LDLR−/− mice fed a HCD. (a) Representative images of the aortic root and (b) quantitative analysis of Oil red O positive area. Oil red O staining was performed to show lipid in aortic root (black arrows ...

After 13 weeks on HCD, the serum levels of TC, TG, and LDL-cholesterol in the HCD group were significantly higher than those in any other group (Fig. (Fig.2a2a--c).c). However, serum TC, TG and LDL-cholesterol levels in the HVC1-treated group (250 mg/kg, p.o.) significantly decreased compared to that in the HCD group. In addition, the HVC1 treated group (250 mg/kg) had increased levels of HDL-cholesterol when compared with the HCD group (Fig. (Fig.2d2d).

Fig. 2
Effect of HVC1 on the serum lipid profile in LDLR−/− mice fed a HCD. Total-cholesterol (a), triglyceride (b), LDL-cholesterol (c), HDL-cholesterol (d). ND: Normal diet group; HCD: High-cholesterol diet group; Sim: Simvastatin (10 mg/kg) ...

Inhibitory effects of HVC1 on expression of PPARs in HCD-fed LDLR−/− mice

The effects of HVC1 on the mRNA expression of PPAR family members in liver tissue were examined by qRT-PCR analysis. As shown in Fig. Fig.3,3, the mRNA expression of PPAR-α in the HCD group was not different from that in the ND group. However, in the HVC1 groups (10, 50, and 250 mg/kg, p.o.), the mRNA expression of PPAR-α significantly increased compared with the HCD group. In addition, administration of HVC1 (250 mg/kg, p.o.) increased the mRNA expression levels of PPAR-δ compared to that in the HCD group, while in the HCD group, PPAR-δ levels significantly decreased compared with the ND group. Conversely, the mRNA expression of PPAR-γ in the HVC1 group significantly decreased compared to that in the HCD group while being significantly higher in the HCD group than in the ND group. Since PPAR-γ plays an important role in adipogenesis and PPAR-γ activation results in reduction of free fatty acid (FFA) efflux and triacylglycerol synthesis [26], we examined PPAR-γ protein expression levels if the expression of PPAR-γ protein paralleled the transcription of its mRNA in LDLR−/− mice. As shown in Fig. Fig.3d,3d, PPAR-γ protein levels increased in the HCD group relative to the ND group. Compared to the HCD group, however, the simvastatin and HVC1-treated groups exhibited marked decrease in the protein levels of PPAR-γ.

Fig. 3
Inhibitory effect of HVC1 on the HCD-induced PPARs expressions in LDLR−/− mice. LDLR−/− mice were randomized into the ND group, HCD group, and treatment groups fed HCD with simvastatin (10 mg/kg) or HVC1 (10, 50 ...

HVC1 regulates lipid metabolism and cholesterol synthesis in HCD-fed LDLR−/−mice

To investigate whether the lipid metabolism and biosynthesis of cholesterol in HVC1 treated mice was associated with molecular signaling by the genes involved in hyperlipidemia, we examined the expression levels of related genes that are key transcription factors in the liver. In the liver tissue, the mRNA expression levels of SREBP-2, HMGCR, LPL, and apo B significantly decreased in a dose dependent manner in the HVC1-treated groups compared to that in the HCD group. Conversely, the expression of LXR mRNA in the HVC1 groups increased compared to that in the HCD group (Fig. (Fig.4a4a--e).e). In addition, treatment with HVC1 markedly increased the expression levels of SREBP-2 and HMGCR in the HCD group compared to that in the ND group. The simvastatin and HVC1-treated groups, however, exhibited reduced expression levels of the proteins (Fig. (Fig.4f4f).

Fig. 4
HVC1 regulation of cholesterol metabolism and lipid synthesis in LDLR−/− mice. Total RNA was subjected to real-time PCR as described in the Methods section. Cholesterol and lipid metabolism-related genes mRNA levels were analyzed by real-time ...

AMPK is a major regulator of energy metabolism, and its phosphorylation is involved in the regulation of adipocyte differentiation [27]; therefore, we investigated whether HVC1 regulated energy metabolism through the AMPK pathway. As shown in Fig. Fig.4g,4g, treatment with HVC1 inhibited HCD-induced dephosphorylation of AMPK in HCD-fed LDLR−/− mice.

Inhibitory effects of HVC1 on mRNA expression of inflammatory cytokines in HCD-fed LDLR−/− mice

Some studies have reported that a correlation exists between plasma total cholesterol and the development of hepatic inflammation [26, 28]. These reports led us to hypothesize that plasma TC as an important cause for the development of inflammation in HCD-fed LDLR−/− mice. Therefore, we investigated the expression of genes associated with inflammation in the liver of HCD-fed LDLR−/− mice. The mRNA expression levels of inflammatory cytokines in the HCD group were significantly up-regulated in comparison to those in the ND group. In contrast, HVC1 markedly reduced the mRNA expression of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β in LDLR−/− mice (Fig. (Fig.5).5). The results suggest that HVC1 treatment may influence the HCD-induced expression of inflammatory genes in LDLR−/− mice.

Fig. 5
Inhibitory effects of HVC1 on mRNA expression of inflammatory cytokines in HCD induced LDLR−/− mice. Inflammatory cytokine genes mRNA levels were analyzed by real-time PCR analysis. (a) TNF-α, (b) IL-1β, (c) IL-6.Total ...

Discussion

Hyperlipidemia is related to increased levels of lipids, including cholesterol and triglyceride in the plasma. Hyperlipidemia increases the risk of developing cardiovascular disease [29]. In this study, we showed the inhibitory effect of HVC1 on hyperlipidemia-related factors in HCD-fed LDLR−/− mice. The effects of HVC1 included regulation of cholesterol synthesis, lipid accumulation, and levels of inflammatory cytokines in HCD-fed mice.

Increased blood lipid levels, especially LDL-cholesterol level, can promote atherosclerosis; therefore, decreasing lipid level is important in reducing atherosclerosis [30, 31]. In this study, HVC1 suppressed the serum levels of LDL-cholesterol, TG, and TC and increased HDL-cholesterol (Fig. (Fig.2).2). These results suggest that HVC1 is crucial for reducing the risk of hyperlipidemia.

PPARs are members of the nuclear hormone receptor superfamily, and they regulate various physiological functions, such as glucose and lipid homeostasis, inflammatory responses, cell differentiation [5]. Lee et al. have reported that PPAR-α and-γ agonists (WY14643 and rosiglitazone) decreased hyperlipidemia by increasing the protein expression of malonyl-CoA decarboxylase (MCD) [32]. PPAR-δ agonists are also reported to have a role in lipid metabolism and they improve metabolic syndrome. They have been noted to enhance HDL cholesterol and decrease LDL cholesterol in insulin-resistant obese monkeys [33]. PPAR-γ plays a role in hyperlipidemia, triglyceride clearance and hepatic steatosis [27, 34]. Some studies reported that HCD administration lead to hepatic damage such as hepatic steatosis in mice [35, 36] and PPAR-γ act as a key modulator of high-fat diet-induced liver steatosis [37, 38]. In this study, we found that HVC1 enhanced the mRNA expression levels of PPAR-α and δ, while HVC1 significantly decreased PPAR-γ mRNA and protein expression levels in liver which is induced to hepatic steatosis. These results suggested that modulation of PPARs expression might be one of the mechanisms by which HVC1attenuates lipid accumulation in hyperlipidemia and hepatic steatosis affected by HCD.

The liver plays a central role in lipid metabolism. Some orphan nuclear hormone receptors such as LXR, retinoid X receptor (RXR), farnesoid X receptor (FXR), and PPAR are related to genes involved in cholesterol metabolism [39, 40]. LXR plays a key important role in cholesterol sensor. LDLR−/− mice have functionally disordered bile acid production, which leads to cholesterol ester accumulation [41]. In addition, SREBP is a transcription factor that regulates the biosynthesis of cholesterol and fatty acids [42]. The precursor of SREBP is synthesized in the endoplasmic reticulum (ER) membrane-bound protein. It is activated, cleaved, and then translocated to the nucleus. SREBP-2 promotes the expression of target genes involved in cholesterol biosynthesis such as 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS), HMGCR and LDLR [43, 44]. HMGCR is a transmembrane protein that is associated with the biosynthesis of cholesterol [45, 46]. In this study, HVC1 decreased the mRNA expression levels of SREBP-2, HMGCR, LPL, and apoB and increased that of LXR in the liver tissue of HCD-fed LDLR−/− mice. In addition, HVC1 markedly increased the protein expression level of SREBP-2 and HMGCR. These data suggested that HVC1 regulated lipid synthesis-related markers through the modulation of adipogenic gene related to cholesterol metabolism.

AMPK is a complex of α/β/γ subunits, which regulate lipid and carbohydrate metabolism, immune response, cell growth, and protein synthesis [47, 48]. AMPK plays an important role in the regulation of fatty acid oxidation by the phosphorylation and inactivation of acetyl-CoA carboxylase (ACC) [49]. It also plays a central role in lipid metabolism in the liver. Hepatic ACC has been found to be regulated in the liver [50]. In addition, AMPK is a key enzyme in cholesterol synthesis via regulation HMGCR [51]. Therefore, AMPK regulates fatty acid oxidation and cholesterol synthesis. The activation of AMPK, results in suppression of lipogenesis in the liver, which inhibits lipid accumulation [52, 53] and AMPK phosphorylation is inhibited in mice fed a HCD [27]. In this study, HVC1 significantly increased AMPK phosphorylation resulting in regulation of lipid metabolism-related genes in HCD-fed LDLR−/−mice (Fig. (Fig.4).4). These findings suggested that hypolipidemic effects of HVC1 could dependent on AMPK pathway in HCD-fed LDLR−/−mice.

Hyperlipidemia not only involves elevation in serum lipids, but it is also an inflammatory disease, as excessive lipid accumulation has been known to trigger local inflammatory reactions [54, 55]. The inflammatory processes mostly coincide with increased local fat accumulation as observed in nonalcoholic steatohepatitis [14]. In addition, inflammatory processes occur during the cardiovascular disease process [33, 56, 57]. Blockade of inflammatory cytokines has been shown to reduce the incidence of cardiovascular disease [29]. In this study, our results showed that HVC1 significantly reduced the mRNA expression levels of inflammatory cytokines (TNF-α, IL-1β, and IL-6) in HCD-fed LDLR−/− mice. Many cytokines participated in the development of atherosclerotic leading to plaque formation [58]. Expression of IL-1-family members and their receptors has been demonstrated in atherosclerotic plaques. Furthermore, inhibition of TNF-α reduces atherosclerosis in apolipoprotein E knockout mice [59]. In these regards, we could suggest that inhibitory effects of HVC1 on mRNA expression levels of inflammatory cytokines are related to the development of atherosclerotic plaque.

Conclusions

We demonstrated that HVC1 has an inhibitory effect of hyperlipidemia involving inflammation in HCD-fed LDLR−/− mice. Our findings indicated that HVC1 treatment could suppress the development of hyperlipidemia via regulation of cholesterol metabolism and inflammatory processes as observed in the HCD-fed LDLR−/− mice. Therefore, HVC1 may be used for the prevention or treatment of hyperlipidemia.

Acknowledgments

This study was supported by a Grant from the Korea Health care Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (B110081).

Availability of data and materials

Data are all contained within the article.

Authors’ contributions

HJA conceived and designed the study. SYC and KSC carried out the experiments, analyzed the research data, and wrote the manuscript. KJL, HYC and IHH participated in the study design and analyzed the research data. DHJ and YYC contributed essential reagents. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abbreviations

LDLR−/−
Low-density lipoprotein receptor-deficient
TG
Triglyceride
LDL
Low-density lipoprotein
HDL
High-density lipoprotein
PPARs
Peroxisome proliferator-activated receptors
SREBP-2
Sterol regulatory element-binding proteins
HMG-CoA reductase
3-hydroxy-3-methylglutaryl
LPL
Lipoprotein lipase
apo B
Apolipoprotein B
LXR
Liver X receptor
AMPK
5′ adenosine monophosphate-activated protein kinase
HCD
High-cholesterol diet
FFA
Free fatty acid
TNF
Tumor necrosis factor
IL
Interleukin
MCD
Malonyl-CoA decarboxylase
ACC
Acetyl-CoA carboxylase

Contributor Information

Se-Yun Cheon, moc.revan@8001yasnuhc.

Kyung-Sook Chung, ten.liamnah@67alleda.

Kyung-Jin Lee, moc.revan@ydutsod.

Ho-Young Choi, rk.ca.uhk@iohcyh.

In-Hye Ham, rk.ca.uhk@mahi.

Dong-Hoon Jung, moc.revan@78elcinirb.

Yun-Yeop Cha, rk.ca.ijgnas@ahcdmo.

Hyo-Jin An, Phone: +82-33-738-7503, rk.ca.js@najh.

References

1. Le NA. Hyperlipidemia and cardiovascular disease. Curr Opin Lipidol. 2006;17(6):702–704. doi: 10.1097/MOL.0b013e328010a05b. [PubMed] [Cross Ref]
2. Gotto AM., Jr Jeremiah Metzger lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Trans Am Clin Climatol Assoc. 2011;122:256–289. [PubMed]
3. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47. doi: 10.1126/science.3513311. [PubMed] [Cross Ref]
4. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92(2):883–893. doi: 10.1172/JCI116663. [PMC free article] [PubMed] [Cross Ref]
5. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 2006;116(3):598–606. doi: 10.1172/JCI27958. [PMC free article] [PubMed] [Cross Ref]
6. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des. 2004;10(22):2779–2786. doi: 10.2174/1381612043383719. [PubMed] [Cross Ref]
7. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20(5):649–688. [PubMed]
8. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cellular and molecular life sciences : CMLS. 2004;61(4):393–416. doi: 10.1007/s00018-003-3216-3. [PubMed] [Cross Ref]
9. Francis GA, Annicotte JS, Auwerx J. PPAR-alpha effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol. 2003;285(1):H1–H9. doi: 10.1152/ajpheart.01118.2002. [PubMed] [Cross Ref]
10. Ory DS. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ Res. 2004;95(7):660–670. doi: 10.1161/01.RES.0000143422.83209.be. [PubMed] [Cross Ref]
11. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003;17(15):2299–2301. [PubMed]
12. Oliver WR, Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001;98(9):5306–5311. doi: 10.1073/pnas.091021198. [PubMed] [Cross Ref]
13. Naya N, Fukao K, Nakamura A, Hamada T, Sugimoto M, Kojima M, Yoshimura N, Uwabe K, Imagawa K, Nomura K, et al. A selective peroxisome proliferator-activated receptor delta agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice. Metab Clin Exp. 2016;65(1):16–25. doi: 10.1016/j.metabol.2015.09.016. [PubMed] [Cross Ref]
14. Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S, Muller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology. 2007;148(6):2753–2763. doi: 10.1210/en.2007-0014. [PubMed] [Cross Ref]
15. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y, Okumura T. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun. 2005;336(1):215–222. doi: 10.1016/j.bbrc.2005.08.070. [PubMed] [Cross Ref]
16. Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia. 2007;50(1):8–17. doi: 10.1007/s00125-006-0492-0. [PubMed] [Cross Ref]
17. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res. 2002;43(2):177–186. [PubMed]
18. Zou ZY, Hu YR, Ma H, Wang YZ, He K, Xia S, Wu H, Xue DF, Li XG, Ye XL. Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters. Fitoterapia. 2015;105:139–146. doi: 10.1016/j.fitote.2015.06.005. [PubMed] [Cross Ref]
19. Yokozawa T, Ishida A, Cho EJ, Nakagawa T. The effects of Coptidis Rhizoma extract on a hypercholesterolemic animal model. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2003;10(1):17–22. doi: 10.1078/094471103321648610. [PubMed] [Cross Ref]
20. Regulska-Ilow B, Biernat J, Grajeta H, Ilow R, Drzewicka M. Influence of bioflavonoids from the radix extract of Scutellaria Baicalensis on the level of serum lipids, and the development of laboratory rats fed with fresh and oxidized fats. Die Nahrung. 2004;48(2):123–128. doi: 10.1002/food.200300382. [PubMed] [Cross Ref]
21. Kim YS, Jung EA, Shin JE, Chang JC, Yang HK, Kim NJ, Cho KH, Bae HS, Moon SK, Kim DH. Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002;25(11):1442–1445. doi: 10.1248/bpb.25.1442. [PubMed] [Cross Ref]
22. Ahn DK. Illustrated book of Korean medicinal herbs: Kyohak. 2006.
23. Kim JG. Illustrated Natural Drugs Encyclopedia (color edition) Vol.1. Seoul: Namsandang; 1992.
24. Ahn TG, Yang G, Lee HM, Kim MD, Choi HY, Park KS, Lee SD, Kook YB, An HJ. Molecular mechanisms underlying the anti-obesity potential of prunetin, an O-methylated isoflavone. Biochem Pharmacol. 2013;85(10):1525–1533. doi: 10.1016/j.bcp.2013.02.020. [PubMed] [Cross Ref]
25. Lee K, Kim B, Hur H, Chinannai KS, Ham I, Choi HY. Antihypertensive effect of the GaMiSamHwangSaSimTang in spontaneous hypertensive rats. Evidence-based complementary and alternative medicine : eCAM. 2015;2015:802368. [PMC free article] [PubMed]
26. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 2008;48(2):474–486. doi: 10.1002/hep.22363. [PubMed] [Cross Ref]
27. Ejaz A, Wu D, Kwan P, Meydani M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr. 2009;139(5):919–925. doi: 10.3945/jn.108.100966. [PubMed] [Cross Ref]
28. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006;4(3):185–198. doi: 10.1016/j.cmet.2006.07.006. [PubMed] [Cross Ref]
29. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1213–1218. [PubMed]
30. Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55(1):35–41. doi: 10.1016/j.jacc.2009.07.057. [PubMed] [Cross Ref]
31. Durrington P. Dyslipidaemia Lancet. 2003;362(9385):717–731. doi: 10.1016/S0140-6736(03)14234-1. [PubMed] [Cross Ref]
32. Luchtefeld M, Grothusen C, Gagalick A, Jagavelu K, Schuett H, Tietge UJ, Pabst O, Grote K, Drexler H, Forster R, et al. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation. 2010;122(16):1621–1628. doi: 10.1161/CIRCULATIONAHA.110.956730. [PubMed] [Cross Ref]
33. Tietge UJ. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol. 2014;25(1):94–95. doi: 10.1097/MOL.0000000000000051. [PubMed] [Cross Ref]
34. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278(36):34268–34276. doi: 10.1074/jbc.M300043200. [PubMed] [Cross Ref]
35. Ganz M, Csak T, Szabo G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol. 2014;20(26):8525–8534. doi: 10.3748/wjg.v20.i26.8525. [PMC free article] [PubMed] [Cross Ref]
36. Lee HJ, Yeon JE, Ko EJ, Yoon EL, Suh SJ, Kang K, Kim HR, Kang SH, Yoo YJ, Je J, et al. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol. 2015;21(45):12787–12799. doi: 10.3748/wjg.v21.i45.12787. [PMC free article] [PubMed] [Cross Ref]
37. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 2000;141(11):4021–4031. [PubMed]
38. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol. 2001;35(1):17–23. doi: 10.1016/S0168-8278(01)00066-6. [PubMed] [Cross Ref]
39. Repa JJ, Mangelsdorf DJ. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr Opin Biotechnol. 1999;10(6):557–563. doi: 10.1016/S0958-1669(99)00031-2. [PubMed] [Cross Ref]
40. Russell DW. Nuclear orphan receptors control cholesterol catabolism. Cell. 1999;97(5):539–542. doi: 10.1016/S0092-8674(00)80763-1. [PubMed] [Cross Ref]
41. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 1998;93(5):693–704. doi: 10.1016/S0092-8674(00)81432-4. [PubMed] [Cross Ref]
42. Matsuda M, Korn BS, Hammer RE, Moon YA, Komuro R, Horton JD, Goldstein JL, Brown MS, Shimomura I. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 2001;15(10):1206–1216. doi: 10.1101/gad.891301. [PubMed] [Cross Ref]
43. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124(1):35–46. doi: 10.1016/j.cell.2005.12.022. [PubMed] [Cross Ref]
44. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331–340. doi: 10.1016/S0092-8674(00)80213-5. [PubMed] [Cross Ref]
45. Bloomfield DK. Dynamics of cholesterol metabolism. I Factors regulating total sterol biosynthesis and accumulation in the rat Proceedings of the National Academy of Sciences of the United States of America. 1963;50:117–124. [PubMed]
46. Bonne AC, den Bieman MG, Gillissen GF, van Lith HA, van Zutphen LF. Chromosomal localization of genes involved in biosynthesis, metabolism or transport of cholesterol in the rat. Cytogenetic and genome research. 2002;97(3–4):183–186. doi: 10.1159/000066606. [PubMed] [Cross Ref]
47. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774–785. doi: 10.1038/nrm2249. [PubMed] [Cross Ref]
48. Steinberg GR, Macaulay SL, Febbraio MA, Kemp BE. AMP-activated protein kinase--the fat controller of the energy railroad. Can J Physiol Pharmacol. 2006;84(7):655–665. doi: 10.1139/y06-005. [PubMed] [Cross Ref]
49. Ouchi N, Shibata R, Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res. 2005;96(8):838–846. doi: 10.1161/01.RES.0000163633.10240.3b. [PubMed] [Cross Ref]
50. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A. 2002;99(25):15983–15987. doi: 10.1073/pnas.252625599. [PubMed] [Cross Ref]
51. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 1998;47(8):1369–1373. [PubMed]
52. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15–25. doi: 10.1016/j.cmet.2004.12.003. [PubMed] [Cross Ref]
53. Wu CH, Yang MY, Chan KC, Chung PJ, Ou TT, Wang CJ. Improvement in high-fat diet-induced obesity and body fat accumulation by a Nelumbo nucifera leaf flavonoid-rich extract in mice. J Agric Food Chem. 2010;58(11):7075–7081. doi: 10.1021/jf101415v. [PubMed] [Cross Ref]
54. van der Heijden RA, Bijzet J, Meijers WC, Yakala GK, Kleemann R, Nguyen TQ, de Boer RA, Schalkwijk CG, Hazenberg BP, Tietge UJ, et al. Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis. Sci Rep. 2015;5:16474. doi: 10.1038/srep16474. [PMC free article] [PubMed] [Cross Ref]
55. Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, Ikeda K, Nakajima Y, Ikura Y, Ueda M, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol. 2007;170(3):967–980. doi: 10.2353/ajpath.2007.060441. [PubMed] [Cross Ref]
56. Navab KD, Elboudwarej O, Gharif M, Yu J, Hama SY, Safarpour S, Hough GP, Vakili L, Reddy ST, Navab M, et al. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease. Curr Pharm Des. 2011;17(1):17–20. doi: 10.2174/138161211795049787. [PubMed] [Cross Ref]
57. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis. 2010;211(2):361–370. doi: 10.1016/j.atherosclerosis.2010.01.011. [PMC free article] [PubMed] [Cross Ref]
58. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5):969–979. doi: 10.1161/ATVBAHA.110.207415. [PubMed] [Cross Ref]
59. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24(11):2137–2142. doi: 10.1161/01.ATV.0000143933.20616.1b. [PubMed] [Cross Ref]

Articles from BMC Complementary and Alternative Medicine are provided here courtesy of BioMed Central